carvedilol has been researched along with atenolol in 82 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.44) | 18.7374 |
| 1990's | 12 (14.63) | 18.2507 |
| 2000's | 37 (45.12) | 29.6817 |
| 2010's | 26 (31.71) | 24.3611 |
| 2020's | 5 (6.10) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Gaillard, P; Schambel, P; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Funakoshi, J; Kakumoto, M; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y | 1 |
| Baker, JG | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chang, Q; Chen, Z; Hu, G; Hu, L; Li, Q; Long, J | 1 |
| Young, PH | 1 |
| Ball, SG; Dixon, S; Hall, S; Hallman, RJ; Harvey, RE; Prescott, RI | 1 |
| Hörrmann, M; Machwirth, M; van der Does, R; Widmann, L | 1 |
| Hörrmann, M; Machwirth, M; Stienen, U; Uberbacher, HJ; van der Does, R; Widmann, L | 1 |
| Härkönen, R; Hilden, M; Icen, R; Kohvakka, A; Linna, M; Lukkala, K; Luurila, OJ; Sillanpää, J; Vänskä, O | 1 |
| Freedman, SB; Harris, PJ; Jamal, SM; Kelly, DT | 1 |
| González Maqueda, I | 1 |
| Ruilope, LM | 1 |
| Gjesdal, K; Klemsdal, TO; Mundal, HH | 1 |
| Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P | 1 |
| Backman, U; Dimény, E; Fellström, B; Johnsson, C; Kaijser, M; Zezina, L | 1 |
| Lercher, P; Liebmann, P; Lindner, W; Maier, R; Sakotnik, A; Stoschitzky, K; Zweiker, R | 1 |
| Ikeda, U; Kurosaki, K; Maeda, Y; Shimada, K | 1 |
| Berger, R; Frey, B; Hülsmann, M; Pacher, R; Stanek, B; Strecker, K | 1 |
| Alimova, EV; Koniakhina, IP; Kutishenko, NP; Lerman, OV; Martsevich, SIu | 1 |
| Jia, Z; Lin, S; Peng, Y; Yang, T; Zhang, Z | 1 |
| Harada, K; Kohmoto, O; Komuro, I; Maruyama, T; Matsui, H; Matsuo, H; Nagai, R; Oyama, T; Serizawa, T; Shimizu, T; Sugishita, Y; Takahashi, T; Yao, A | 1 |
| Eide, I; Fossum, E; Høieggen, A; Jonsson, G; Kjeldsen, SE; Os, I; Westheim, A | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Pfeffer, M | 1 |
| Choy, AM; Herman, RB; Husain, R; Jesudason, PJ; Lang, CC; Mustafa, AM | 1 |
| Hammer, D; Merritt, JC; Mills, RM; Niebauer, M; Tarakji, K | 1 |
| Cha, KS; Kim, DI; Kim, DS; Kim, HJ; Kim, JS; Kim, JW; Kim, MH | 1 |
| Eschenhagen, T; Rau, T; Wuttke, H | 1 |
| Altieri, P; Ballestrero, A; Barsotti, A; Brunelli, C; Fabbi, P; Garibaldi, S; Ghigliotti, G; Manca, V; Nasti, S; Patrone, F; Rossettin, P; Spallarossa, P | 1 |
| Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG | 1 |
| Abdelnoor, M; Jonsson, G; Kjeldsen, SE; Müller, C; Os, I; Westheim, A | 1 |
| Fabryova, V; Jancinova, V; Majekova, M; Nosal, R; Petrikova, M | 1 |
| Altieri, P; Barisione, C; Barsotti, A; Brunelli, C; Fabbi, P; Garibaldi, S; Ghigliotti, G; Manca, V; Patrone, F; Spallarossa, P | 1 |
| Andrews, M; Brodine, WN; Daubert, JP; Hall, WJ; Hockstad, ES; Lee, JK; McNitt, S; Moss, AJ; Tung, RT; Zareba, W | 1 |
| Iakovleva, MS; Mironova, MA; Sadionchenko, VS; Shekhian, GG | 1 |
| Ko, YS; Lee, PY; Su, CH; Tian, TY; Tsai, CH; Yeh, HI | 1 |
| Fonarow, GC | 1 |
| Oguz, A; Uzunlulu, M; Yorulmaz, E | 1 |
| Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA | 1 |
| Cai, Y; Jia, J; Li, S; Liu, G; Liu, Y; Pan, C; Ren, J; Yu, C | 1 |
| Abdelnoor, M; Arnesen, H; Hostmark, AT; Jonsson, G; Kjeldsen, SE; Os, I; Seljeflot, I; Westheim, AS | 1 |
| Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA | 1 |
| Cockcroft, JR; Pedersen, ME | 1 |
| Go, AS; Gurwitz, JH; Hsu, J; Lane, K; Platt, R; Yang, J | 1 |
| Aronson, JK | 1 |
| Baek, IH; Kwon, KI; Yun, HY; Yun, MH | 1 |
| Black, HR; Sica, DA | 1 |
| Du, CK; Ide, T; Lu, QW; Miwa, Y; Morimoto, S; Sasaguri, T; Takahashi-Yanaga, F; Tanaka, A; Wang, YY; Zhan, DY | 1 |
| Barbosa, L; Bertoquini, S; Polónia, J; Silva, JA | 1 |
| Pisklak, DM; Wawer, I; Zielińska-Pisklak, MA | 1 |
| Ashfaq, U; Epstein, BJ; Johnson, JA; Lo, MC; Nichols, WW; Satish, P; Shah, NK; Smith, SM | 1 |
| DiNicolantonio, JJ; Hackam, DG | 1 |
| Blum, SI; Chen, S; Marynchenko, M; Ramakrishnan, K; Ramasamy, A; Samuelson, TM; Signorovitch, JE; Wu, EQ | 1 |
| Benvenuto, A; Masciocco, L; Prencipe, G; Riccioni, G; Rizzo, U; Russi, C; Speziale, G; Ventra, S | 1 |
| DiNicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; O'Keefe, JH | 1 |
| Bertera, FM; Chiappetta, D; Del Mauro, JS; Höcht, C; Lovera, V; Polizio, AH; Taira, CA | 1 |
| Antenore, A; Bagnoli, P; Dicembrini, I; Filippi, L; Mannucci, E; Marchionni, N; Monami, M; Rotella, CM; Sgrilli, F; Ungar, A | 1 |
| Ripley, TL; Saseen, JJ | 1 |
| Annaert, P; Augustijns, P; Stappaerts, J; Tack, J; Wuyts, B | 1 |
| Andresen, BT; Chang, A; Huang, KM; Huang, Y; Jackson, EK; Kanassatega, RS; Liu, MM; Orlando, R; Parsa, C; Thakkar, A; Yeung, S | 1 |
| Coelho, M; Correia, G; Medeiros, R; Moz, M; Ribeiro, L; Teixeira, A | 1 |
| Ahn, T; Kang, WC; Kim, MG; Kim, S; Lee, K; Moon, J; Oh, PC; Park, YM; Shin, EK | 1 |
| Chen, RJ; Chu, H; Tsai, LW | 1 |
| Komal, C; Prachi, S; Priti, MJ | 1 |
| Hamaguchi, S; Hasegawa, N; Ichige, S; Irie, M; Mochizuki, S; Namekata, I; Shimobayashi, M; Tanaka, H; Tanaka, Y; Tsuneoka, Y | 1 |
| Casali, KR; Dartora, DR; Dias, LD; Eibel, B; Irigoyen, MC; Kalil, RAK; Kristochek, M; Lehnen, AM; Markoski, MM; Peres, TR | 1 |
| Addison, D; Alam, M; Jneid, H; Kayani, W; Lakkis, N; Misra, A; Pham, D; Resar, J | 1 |
| Egan, B; Flack, J; Lombera, S; Patel, M | 1 |
| Andrews, LM; Koch, BCP; van der Nagel, BCH; van Domburg, B | 1 |
| Agalliu, I; Fram, E; Frenette, PS; Lin, W; Mohn, L; Watts, KL; Zahalka, AH | 1 |
| Jacobsen, SJ; Kalantar-Zadeh, K; Kovesdy, CP; Lee, MS; Neyer, JR; Shaw, SF; Shi, J; Sim, JJ; Zhou, H | 1 |
| Chan You, S; Chen, R; Duke, J; Hripcsak, G; Krumholz, HM; Madigan, D; Park, S; Pratt, N; Reich, CG; Ryan, PB; Schuemie, MJ; Shea, S; Suchard, MA; Woong Park, R | 1 |
| Abd El Motteleb, DM; Elshazly, SM; Mohamed, RMSM; Nafea, OE | 1 |
10 review(s) available for carvedilol and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alleles; Atenolol; Benzopyrans; Biotransformation; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Ethanolamines; Female; Genotype; Humans; Male; Metoprolol; Mutation; Nebivolol; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Propanolamines; Risk Factors; Time Factors | 2004 |
Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations.
Topics: Adrenergic beta-Antagonists; Algorithms; Atenolol; Carbazoles; Carvedilol; Humans; Myocardial Infarction; Practice Guidelines as Topic; Propanolamines; Propranolol; Randomized Controlled Trials as Topic; Secondary Prevention; Timolol | 2006 |
The vasodilatory beta-blockers.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Antioxidants; Atenolol; Benzopyrans; Blood Pressure; Carbazoles; Cardiac Output; Cardiovascular Diseases; Carvedilol; Endothelium, Vascular; Ethanolamines; Hemodynamics; Humans; Labetalol; Nebivolol; Propanolamines; Vascular Resistance; Vasodilation; Ventricular Function, Left | 2007 |
Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Atenolol; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Humans; Hypertension; Nebivolol; Practice Guidelines as Topic; Propanolamines | 2008 |
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; Biomarkers; Carbazoles; Carvedilol; Humans; Hypertension; Metoprolol; Myocardial Infarction; Propanolamines; Secondary Prevention; Sympathetic Nervous System; Vasodilator Agents | 2012 |
Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Ethanolamines; Global Health; Humans; Metoprolol; Myocardial Infarction; Nebivolol; Platelet Aggregation Inhibitors; Propanolamines; Survival Rate; Treatment Outcome | 2013 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabetes Mellitus; Ethanolamines; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Myocardial Ischemia; Nebivolol; Neoplasms; Propanolamines; Risk | 2013 |
β-blockers: a review of their pharmacological and physiological diversity in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; Carbazoles; Carvedilol; Ethanolamines; Humans; Hypertension; Metoprolol; Nebivolol; Propanolamines | 2014 |
Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carvedilol; Cocaine; Humans; Metoprolol; Propanolamines; Propranolol | 2018 |
27 trial(s) available for carvedilol and atenolol
| Article | Year |
|---|---|
A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Propanolamines; Vasodilator Agents | 1992 |
A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Delayed-Action Preparations; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Propanolamines; Vasodilator Agents | 1991 |
Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Lipoproteins; Male; Middle Aged; Propanolamines; Randomized Controlled Trials as Topic; Triglycerides | 1990 |
Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Patient Compliance; Propanolamines; Randomized Controlled Trials as Topic | 1990 |
Carvedilol and atenolol once daily in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Carbazoles; Carvedilol; Double-Blind Method; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Propanolamines; Randomized Controlled Trials as Topic | 1989 |
Comparison of carvedilol and atenolol for angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Propanolamines; Random Allocation | 1987 |
Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Cholesterol; Doxazosin; Electrocardiography, Ambulatory; Endothelium, Vascular; Ergometry; Female; Fibrinolysis; Heart Rate; Humans; Hypertension; Lipoproteins; Male; Middle Aged; Myocardial Ischemia; Propanolamines; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides | 1994 |
Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Kidney Function Tests; Lipids; Liver Function Tests; Male; Middle Aged; Propanolamines; Single-Blind Method | 1994 |
Effects of carvedilol and atenolol on arterial pulse curves (plethysmography) and finger temperature after hand cooling.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Circulation; Body Temperature; Carbazoles; Carvedilol; Fingers; Hemodynamics; Humans; Hypothermia; Male; Plethysmography; Propanolamines | 1996 |
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Glucose; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Hypertension; Lipid Peroxidation; Lipids; Male; Middle Aged; Propanolamines; Single-Blind Method | 1997 |
Influence of beta-blockers on melatonin release.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Carbazoles; Carvedilol; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Hemodynamics; Humans; Male; Melatonin; Propanolamines; Propranolol; Stereoisomerism; Verapamil | 1999 |
[Comparison of carvedilol and atenolol efficacy in patients with stable effort angina].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Animals; Atenolol; Carbazoles; Carvedilol; Double-Blind Method; Humans; Male; Middle Aged; Propanolamines | 2001 |
[Efficacy of native carvedilol in patients with essential hypertension].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Carbazoles; Carvedilol; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Propanolamines | 1999 |
Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction.
Topics: Adrenergic alpha-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Blood Viscosity; Carbazoles; Carvedilol; Epinephrine; Female; Forearm; Glucose Clamp Technique; Heart Rate; Humans; Male; Middle Aged; Myocardial Infarction; Norepinephrine; Propanolamines; Regional Blood Flow; Vascular Resistance | 2002 |
Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Exercise; Exercise Test; Heart Rate; Humans; Male; Norepinephrine; Propanolamines | 2003 |
Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; Carbazoles; Carvedilol; Coronary Disease; Coronary Restenosis; Female; Humans; Hyperplasia; Male; Middle Aged; Myocardial Infarction; Propanolamines; Stents; Tunica Intima | 2004 |
A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carbazoles; Carvedilol; Female; Gated Blood-Pool Imaging; Humans; Male; Middle Aged; Myocardial Infarction; Propanolamines; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2005 |
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carbazoles; Carvedilol; Defibrillators, Implantable; Female; Follow-Up Studies; Humans; Male; Metoprolol; Myocardial Ischemia; Propanolamines; Prospective Studies; Stroke Volume; Survival Rate; Tachycardia; Treatment Outcome | 2005 |
[Carvedilol in combined therapy of patients with Q myocardial infarction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atenolol; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Hemodynamics; Humans; Long QT Syndrome; Male; Middle Aged; Myocardial Infarction; Propanolamines; Vasodilator Agents | 2005 |
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthropometry; Antihypertensive Agents; Atenolol; Carbazoles; Carvedilol; Cholesterol, HDL; Doxazosin; Drug Administration Schedule; Female; Humans; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Propanolamines; Prospective Studies; Risk Factors | 2006 |
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients.
Topics: Antioxidants; Atenolol; Carbazoles; Carvedilol; Female; Humans; Long-Term Care; Male; Middle Aged; Myocardial Infarction; Propanolamines; Prospective Studies; Time | 2007 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response Relationship, Drug; Female; Fibrosis; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Peptide Fragments; Procollagen; Propanolamines; Prospective Studies; Radioimmunoassay; Spironolactone | 2007 |
Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Asian People; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Humans; Korea; Male; Models, Cardiovascular; Propanolamines | 2008 |
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Artery; Carbazoles; Carvedilol; Heart Ventricles; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Propanolamines; Statistics, Nonparametric | 2011 |
Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Stable; Atenolol; Benzazepines; Bisoprolol; Carbazoles; Carvedilol; Female; Health Surveys; Humans; Ivabradine; Male; Middle Aged; Propanolamines; Quality of Life | 2013 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabetes Mellitus; Ethanolamines; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Myocardial Ischemia; Nebivolol; Neoplasms; Propanolamines; Risk | 2013 |
Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angina, Stable; Atenolol; Carbazoles; Cardiotonic Agents; Carvedilol; Cholesterol; Exercise Test; Female; Heart; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Myocardial Infarction; Propanolamines; Republic of Korea; Risk; Self Report; Vasodilator Agents | 2016 |
46 other study(ies) available for carvedilol and atenolol
| Article | Year |
|---|---|
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
Topics: Indoles; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Propanolamines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Structure-Activity Relationship; Tetrahydronaphthalenes | 1996 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Interaction of digoxin with antihypertensive drugs via MDR1.
Topics: Animals; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Digoxin; Drug Interactions; Humans; Time Factors | 2002 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Docking Simulation; Molecular Structure; Propanols; Skin Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Cyclosporine; Drug Interactions; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Propanolamines; Vasodilator Agents | 1997 |
Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Atenolol; Carbazoles; Carvedilol; Dactinomycin; Drug Synergism; Enzyme Induction; Enzyme Inhibitors; Guanidines; Heart; Interleukin-1; Isoproterenol; Muscle Proteins; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Nucleic Acid Synthesis Inhibitors; Propanolamines; Propranolol; Rats; Rats, Sprague-Dawley; Recombinant Proteins | 2000 |
Experience with beta-blocker therapy in patients with advanced heart failure evaluated for HTx.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enalapril; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Propanolamines; Retrospective Studies; Risk Assessment; Survival Rate | 2000 |
Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca2+]i in ventricular myocytes compared with those of timolol and atenolol.
Topics: Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Calcium; Calcium Channels, L-Type; Carbazoles; Carvedilol; Guinea Pigs; Heart Ventricles; In Vitro Techniques; Intracellular Membranes; Male; Myocytes, Cardiac; Osmolar Concentration; Propanolamines; Receptors, Adrenergic, beta; Timolol | 2003 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Carbazoles; Carvedilol; Drug Approval; Humans; Hypertension; Losartan; Middle Aged; Myocardial Infarction; Propanolamines; Racial Groups; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk; Stroke; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Male; Metoprolol; Middle Aged; Outcome Assessment, Health Care; Postoperative Complications; Propanolamines; Retrospective Studies; Vasodilator Agents | 2003 |
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Atenolol; bcl-2-Associated X Protein; Carbazoles; Carvedilol; Caspase 3; Caspases; Cells, Cultured; DNA Fragmentation; Doxorubicin; Free Radicals; Gene Expression; Myocytes, Cardiac; Propanolamines; Proto-Oncogene Proteins c-bcl-2; Rats; RNA, Messenger | 2004 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Baroreflex; Bisoprolol; Carbazoles; Carvedilol; Data Interpretation, Statistical; Death, Sudden, Cardiac; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Perindopril; Phenylephrine; Propanolamines; Time Factors; Ventricular Dysfunction, Left | 2004 |
Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets.
Topics: Adrenergic beta-Antagonists; Atenolol; Carbazoles; Carvedilol; Humans; In Vitro Techniques; Platelet Aggregation; Platelet Aggregation Inhibitors; Propanolamines; Propranolol; Thromboxane B2 | 2005 |
Doxorubicin-induced expression of LOX-1 in H9c2 cardiac muscle cells and its role in apoptosis.
Topics: Acetylcysteine; Animals; Apoptosis; Atenolol; Carbazoles; Carvedilol; Cell Line; Doxorubicin; Flow Cytometry; Free Radicals; Hydrogen Peroxide; Myocytes, Cardiac; Propanolamines; Rats; Razoxane; Receptors, LDL; Receptors, Oxidized LDL; RNA, Messenger; Scavenger Receptors, Class E; Up-Regulation | 2005 |
Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Atenolol; Biomarkers; Blood Pressure; Blotting, Northern; Blotting, Western; Carbazoles; Carvedilol; Cells, Cultured; Connexin 43; Connexins; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Follow-Up Studies; Gap Junction alpha-4 Protein; Humans; Hypertension; Immunohistochemistry; In Vitro Techniques; Microscopy, Confocal; NG-Nitroarginine Methyl Ester; Propanolamines; Rats; Rats, Sprague-Dawley; Time Factors; Treatment Outcome; Umbilical Veins | 2006 |
Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atenolol; Carbazoles; Carvedilol; Chi-Square Distribution; Chronic Disease; Drug Therapy, Combination; Drug Utilization; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Male; Metoprolol; Middle Aged; Pharmacoepidemiology; Practice Patterns, Physicians'; Propanolamines; Proportional Hazards Models; Risk Factors; Time Factors; United States; United States Department of Veterans Affairs; Warfarin | 2006 |
Simultaneous determination of ten antiarrhythic drugs and a metabolite in human plasma by liquid chromatography--tandem mass spectrometry.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Chromatography, Liquid; Diltiazem; Humans; Metoprolol; Mexiletine; Molecular Structure; Propanolamines; Propranolol; Reproducibility of Results; Sotalol; Tandem Mass Spectrometry; Verapamil | 2007 |
Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aluminum; Atenolol; California; Carbazoles; Carvedilol; Confidence Intervals; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Patient Readmission; Propanolamines; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tartrates; Time Factors; Treatment Outcome | 2007 |
Changing beta-blockers in heart failure: when is a class not a class?
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Heart; Heart Failure; Humans; Natriuretic Peptide, Brain; Propanolamines | 2008 |
Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Models, Animal; Electrocardiography; Metoprolol; Mice; Mutation; Propanolamines; Troponin T; Ventricular Function, Left | 2009 |
Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Aorta; Atenolol; Benzopyrans; Blood Flow Velocity; Blood Pressure; Brachial Artery; Calcium Channel Blockers; Carbazoles; Carvedilol; Dihydropyridines; Diuretics; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nebivolol; Propanolamines; Pulsatile Flow; Retrospective Studies; Vascular Resistance; Vasodilator Agents | 2010 |
1H and 13C NMR characteristics of β-blockers.
Topics: Acebutolol; Acids; Adrenergic beta-Antagonists; Alkalies; Alprenolol; Atenolol; Carbazoles; Carbon Isotopes; Carvedilol; Nuclear Magnetic Resonance, Biomolecular; Pindolol; Propanolamines; Propranolol; Protons; Timolol | 2011 |
Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Carbazoles; Carvedilol; Databases, Factual; Ethanolamines; Female; Humans; Hypertension; Insurance Claim Review; Male; Metoprolol; Middle Aged; Nebivolol; Propanolamines; Retrospective Studies | 2012 |
Acute effects of third generation β-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats.
Topics: Adrenergic beta-Antagonists; Animals; Arterial Pressure; Atenolol; Benzopyrans; Blood Pressure; Calcium Channel Blockers; Carbazoles; Carvedilol; Denervation; Dose-Response Relationship, Drug; Ethanolamines; Heart Rate; Male; Nebivolol; Propanolamines; Rats; Rats, Wistar; Sinoatrial Node; Verapamil | 2013 |
Human and simulated intestinal fluids as solvent systems to explore food effects on intestinal solubility and permeability.
Topics: Animals; Atenolol; Body Fluids; Carbazoles; Carvedilol; Humans; Intestinal Secretions; Male; Metoprolol; Permeability; Propanolamines; Propranolol; Rats; Rats, Sprague-Dawley; Solubility; Solvents | 2014 |
Prevention of skin carcinogenesis by the β-blocker carvedilol.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adrenergic beta-Antagonists; Animals; Anticarcinogenic Agents; Atenolol; Carbazoles; Carvedilol; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Isoproterenol; Mice; Mutation; Neoplasm Transplantation; Propanolamines; Skin Neoplasms; Transcription Factor AP-1 | 2015 |
Antiproliferative effects of β-blockers on human colorectal cancer cells.
Topics: Adenocarcinoma; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Atenolol; Carbazoles; Carvedilol; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Epinephrine; HT29 Cells; Humans; Isoproterenol; Norepinephrine; Propanolamines; Propranolol; Receptors, Adrenergic, beta; Signal Transduction | 2015 |
Impact of Beta-Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Population-Based Cohort Study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Hospital Mortality; Humans; Male; Metoprolol; Middle Aged; Mortality; Odds Ratio; Perioperative Care; Propanolamines; Propensity Score; Protective Factors; Risk Factors; Surgical Procedures, Operative; Taiwan; Time Factors | 2017 |
Influence of Peroxide Impurities in Povidone on the Stability of Selected β-Blockers with the Help of HPLC.
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Excipients; Metoprolol; Oxidation-Reduction; Peroxides; Povidone; Propanolamines | 2017 |
Involvement of alpha- and beta-adrenoceptors in the automaticity of the isolated guinea pig pulmonary vein myocardium.
Topics: Animals; Atenolol; Atrial Fibrillation; Carbazoles; Carvedilol; Guinea Pigs; In Vitro Techniques; Male; Membrane Potentials; Myocardium; Norepinephrine; Prazosin; Propanolamines; Pulmonary Veins; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Vasoconstriction | 2017 |
β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; beta-Arrestin 1; beta-Arrestin 2; Carbazoles; Carvedilol; Cell Movement; Chemokine CXCL12; Disease Models, Animal; G-Protein-Coupled Receptor Kinase 2; Hypertension; Kidney; Liver; Lung; Metoprolol; Myocardium; NF-kappa B; Propanolamines; Propranolol; Rats, Inbred SHR; Receptors, CXCR; Receptors, CXCR4; Signal Transduction | 2018 |
Insights on β-blockers for the treatment of hypertension: A survey of health care practitioners.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black or African American; Cardiologists; Carvedilol; Heart Rate; Humans; Hypertension; Metoprolol; Nebivolol; Perception; Physicians, Primary Care; Practice Guidelines as Topic; Surveys and Questionnaires; Vasodilation | 2018 |
High-throughput quantification of ten antiarrhythmic drugs in human plasma using UPLC-MS/MS.
Topics: Anti-Arrhythmia Agents; Atenolol; Bisoprolol; Carvedilol; Chromatography, High Pressure Liquid; Diltiazem; Flecainide; High-Throughput Screening Assays; Humans; Lidocaine; Metoprolol; Propranolol; Reproducibility of Results; Sotalol; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Verapamil | 2019 |
Use of beta-blocker types and risk of incident prostate cancer in a multiethnic population.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carvedilol; Humans; Image-Guided Biopsy; Incidence; Male; Metoprolol; Middle Aged; Prostate; Prostatic Neoplasms; Protective Factors; Retrospective Studies; Risk Assessment; Time Factors; Ultrasonography, Interventional | 2020 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Death; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Labetalol; Logistic Models; Male; Metoprolol; Middle Aged; Mortality; Nadolol; Proportional Hazards Models; Propranolol; Protective Factors; Renal Dialysis; Retrospective Studies; Risk; Risk Factors | 2021 |
Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Carvedilol; Databases, Factual; Female; Humans; Hypertension; Male; Middle Aged; Nebivolol; Treatment Outcome | 2021 |
Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4.
Topics: Animals; Apoptosis; Atenolol; beta-Arrestin 2; Blood Pressure; Cardio-Renal Syndrome; Cardiomegaly; Cardiotonic Agents; Carvedilol; Diacylglycerol Kinase; Disease Models, Animal; Kidney; Male; Myocardium; Nephrectomy; Phosphatidylinositol 4,5-Diphosphate; Rats, Wistar; Receptors, Adrenergic, beta-1 | 2021 |